Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic adipose-derived mesenchymal stem cells for diabetic foot ulcer
2024-518533-29-00Phase 2Authorised
- Sponsor
- Medical University of Warsaw
- Start
- Dec 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSCC_ASC in diabetic foot ulcer (DFU) (2 arms), sponsored by Medical University of Warsaw. Primary endpoints: Change in wound surface area, Adverse events and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
CSCC_ASC
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2024-518533-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518533-29-00.